Shares of Immunome (IMNM), a biotechnology company specializing in targeted oncology therapies, have dropped more than 50% from their 52-week high of $30.96, recorded in March, to trade around $13.
Immunome's lead drug candidate, AL102, is currently in a Phase 3 portion, of the Phase II/III trial, for the treatment of desmoid tumors, a rare and debilitating type of soft tissue cancer, dubbed RINGSIDE Part B.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.